Login to Your Account



BIO CEO & Investor Conference

Biotech's Challenge: Balancing R&D with Shareholder Returns

By Michael Harris
Staff Writer

Tuesday, February 14, 2012

NEW YORK – An age-old problem with the business-as-usual model in the biotech market is that the objectives of the principal stakeholders are integrally at odds with one another. The executives, investors and researchers who make things happen in the drug development world all want to see their drugs approved or they want to experience an exit strategy come to fruition, but they have different ideologies on achieving that goal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription